Evidence map›Paper›PMID 34498112›Full record

ArticleRheumatology international2021

A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany.

Rebecca Hasseli, Alexander Pfeil, Andreas Krause, Hendrik Schulze-Koops, Ulf Müller-Ladner, Christof Specker, COVID-19 Task Force of the German Society for Rheumatology (DGRh)

Open access · hybridAbstract read
In one paragraph

Article in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. [The German COVID-19 rheumatism register].Zeitschrift fur Rheumatologie · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Rebecca HasseliDepartment of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Bad Nauheim, Germany. r.hasseli@kerckhoff-klinik.de.ORCID http://orcid.org/0000-0002-2982-8253
Alexander PfeilDepartment of Internal Medicine III, University Hospital Jena, Jena, Germany.ORCID http://orcid.org/0000-0002-2709-6685
Andreas KrauseDepartment of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital, Berlin, Germany.
Hendrik Schulze-KoopsDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-1681-491X
Ulf Müller-LadnerDepartment of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Bad Nauheim, Germany.
Christof SpeckerDepartment of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Essen, Germany.ORCID http://orcid.org/0000-0003-2504-3229
COVID-19 Task Force of the German Society for Rheumatology (DGRh)
Justus-Liebig-Universität Gießen · DEImmanuel Krankenhaus · DEJena University Hospital · DEKliniken Essen-Mitte · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective is to evaluate the attitude of rheumatologists regarding the use of COVID-19 vaccination in patients with inflammatory rheumatic diseases (IRDs). From February 2nd until March 15th, 2021, rheumatologists from Germany were asked to participate anonymously in a survey addressing their attitude with respect to COVID-19 vaccinations of IRD patients. The survey was completed by 214 participants (107 men, 103 women, 4 unspecified). More than half of the physicians (61%) were working in rheumatologic private practices and 62% had more than 20 years of experience in rheumatology. 90% reported to be at least confidential in handling issues of COVID-19 vaccination and 99% would recommend COVID-19 vaccination for IRD patients. The majority would not recommend to stop or reduce immunomodulatory drugs for vaccination except for rituximab. More than 70% would prefer vaccination with a mRNA vaccine for their IRD patients. This study shows that almost all rheumatologists in Germany support the COVID-19 vaccination for their IRD patients without reducing or terminating the actual immunomodulatory medication to potentially improve the response to the vaccine. This attitude is in accordance with the current recommendations of the German Society of Rheumatology regarding COVID-19 vaccination in IRD patients, and indicates that these have been well accepted and work in everyday clinical practice.

Indexed as

Attitude of Health PersonnelHealth Knowledge, Attitudes, PracticeAdultAgedCOVID-19 VaccinesCross-Sectional StudiesFemaleGermanyHumansMaleMiddle AgedRheumatic DiseasesRheumatologistsRheumatologySurveys and QuestionnairesCOVID-19 VaccinesCOVID-19 vaccinesGlucocorticoidsImmunmodulatory drugsInflammatory rheumatic diseasesRituximab

Identifiers

PMID34498112
PMCPMC8425463
OpenAlexW3197840293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.